drugset / Trial / NCT00418275
Safety Study of a Recombinant Human Plasminogen Activator to Treat Acute Ischemic Stroke.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the safety profiles of HTU-PA in patients with acute ischemic stroke.
Timeline
- Start
- 2001-04
- Primary completion
- —
- Completion
- 2004-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human tissue urokinase type plasminogen activator | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |
| Subject | human tissue urokinase type plasminogen activator | Protein / enzyme biologic | 0.35 mg/kg | Intravenous |
| Subject | human tissue urokinase type plasminogen activator | Protein / enzyme biologic | 0.4 mg/kg | Intravenous |